Recipharm makes senior appointments as transition to low global warming potential propellants in pressurised Metered Dose Inhalers gains pace

Global contract development and manufacturing organisation (CDMO), Recipharm has today announced the appointment of Richard Turner as Head of Business Development, and Jeremy Tidmarsh as Site Director, Holmes Chapel, to its Advanced Delivery Systems business unit, as it continues to accelerate its ambition to supply low global warming potential (GWP) pressurised Metered Dose Inhalers (pMDIs) in response to customer demand.

Richard joins Recipharm from H&T Presspart, where he was Global Sales Director. Having spent 22 years developing H&T Presspart's pMDI components business, Richard is ideally placed to lead Recipharm's business development team to partner with customers worldwide. Richard and his team will focus on supporting customers with pMDI product development, fully finished clinical and commercial scale pMDI supply, and device and component development and supply, including the market-leading Bespak® range of pMDI valves, actuators, and dose counters.

Jeremy joins Recipharm from Wockhardt UK, where he was Site Director of technical operations. Having previously worked for Ipsen Biopharm and Reckitt Benckiser Health, Jeremy brings a wealth of experience in pharmaceuticals manufacturing and packing, supply chain, and leadership of global transformation and efficiency programmes. Jeremy and his team will focus on operations to support Recipharm's growth at the site which supplies pMDIs worldwide, and will further develop its capability to supply low-GWP inhalers.

These appointments come as Recipharm announced its collaboration with Honeywell to speed up the development of inhalers with a near-zero GWP propellant, Honeywell Solstice® Air (HFO-1234ze(E) cGMP). This announcement follows recent news on the expansion of its pMDI product development and manufacturing capabilities to accommodate increased demand from pharmaceutical companies.

Commenting on these appointments, Chris Hirst, President of Recipharm's Advanced Delivery Systems business unit said: "I am delighted that both Richard and Jeremy have chosen to join Recipharm at this exciting time as we build our capabilities and capacity to serve our customers in their transition to low-GWP propellant pMDIs. Combined with our collaboration with Honeywell, and our expertise in valves and actuators under our Bespak® brand, we aim to be the partner of choice for companies developing their pMDI portfolios to embrace more sustainable respiratory care."

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals and biologics in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com

Contact information
Fiona Whyatt, ramarketing PR, [email protected]

Recipharm AB
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com